ClinicalTrials.gg
CompletedNCT03252496Updated Sep 5, 2021

Combined Colloids And Crystalloids Versus Crystalloids in Women With Preeclampsia Undergoing Cesarean Delivery

An interventional study of Spinal Anesthesia and Intrathecal Bupivacaine in Pre-Eclampsia and Cesarean Section, sponsored by Mansoura University. Completed at 1 site in Egypt. Open to female participants aged 19 Years to 40 Years. Per ClinicalTrials.gov, last updated 2021-09-05.

Sponsored by Mansoura University · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
19 Years to 40 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 79 studies in Pre-Eclampsia with a site in Egypt — 11 open to participants now, 12 under way, none of them phase 3. Pre-Eclampsia · Egypt.

Enrollment
13th of 40
140 · median 100
Started
2017
with 10 others
No phase
21 of 79
5 open now
Registered
19th of 79
by date
Lead sponsor
3 of 79
Mansoura University

Among the 79 studies in Pre-Eclampsia with a site in Egypt, this one is the 13th largest by enrollment of the 40 interventional ones that give a count, is one of 11 that started in 2017, is one of 21 with no phase, and was the 19th registered.

Pre-Eclampsia

918 studies on the registry are indexed under Pre-Eclampsia; 244 are open to participants now.

Browse Pre-Eclampsia studies →

Open to participants now

11 of the 79 studies in Pre-Eclampsia with a site in Egypt are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 161 Pre-Eclampsia studies recruiting now, 80 (50%) set no upper age limit and 80 (50%) stop at 75 or younger; 18 take children under 18; 60 take healthy volunteers.

This study: 19 Years to 40 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 79 studies in Pre-Eclampsia with a site in Egypt, or all of them as a file.
02

Study summary

This study will compare between combination of colloids/crystalloids and crystalloids in women with preeclampsia undergoing elective cesarean delivery under spinal anesthesia

Read the detailed description

This randomized, controlled, double blind study will be conducted on women with preeclampsia with singleton pregnancy undergoing elective cesarean delivery under spinal anesthesia. Immediately, after spinal anesthesia administration, patients will receive either 250 mL colloid over 5 minutes followed by 500 mL crystalloid over 55 minutes then 250 mL colloid over 60 minutes (Combination group) or 250 mL crystalloid over 5 minutes followed by 500 mL over 55 minutes then 250 mL over 60 minutes (Crystalloid group). The studied maternal outcomes will be the urine output, ephedrine requirement, incidence of hypotension, inferior vena cava diameters, nausea/vomiting and bradycardia. Neonatal Apgar scores will be recorded at 1 and 5 minutes post-delivery.

03

Conditions studied

  • Pre-Eclampsia
  • Cesarean Section

Browse trials for

04

Who can participate

Ages eligible
19 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Preeclampsia: Blood Pressure ≥140/90 mmHg after 20 weeks' gestation and proteinuria ≥300 mg/24 hours or 1+ on urine dipstick
  • Singleton pregnancy
  • Elective cesarean delivery under spinal anesthesia

Exclusion criteria

Exclusion Criteria:

  • Height \<150 cm
  • Weight \<60 kg
  • ≥45 kg/m2
  • Women presenting in labor
  • to spinal anesthesia (increased intracranial pressure or local skin infection)
  • Diabetes mellitus, cardiovascular, cerebrovascular, or renal disease
  • Preoperative administration of intravenous hydralazine or magnesium sulphate
  • \<10 gm/dL
  • >1.3
  • count \<100,000 /mm3
  • Preoperative serum creatinine >1.1 mg/dL
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
140 participants (actual)

Study arms

  • Experimental
    Combination

    250 mL colloid over 5 minutes followed by 500 mL crystalloid over 55 minutes then 250 mL colloid over 60 minutes. Cesarean delivery performed under spinal anesthesia (intrathecal bupivacaine 12.5 mg and intrathecal fentanyl 15 μg). Ultrasound assessment of the Inferior vena cava diameter. Intravenous ephedrine and intravenous syntocinon will be administered.

    Procedure: Spinal Anesthesia · Drug: Intrathecal Bupivacaine · Drug: Intrathecal Fentanyl · Procedure: Cesarean Delivery · Radiation: Ultrasound Assessment of the Inferior Vena Cava · Drug: 250 mL Colloid over 5 minutes · Drug: 500 mL Crystalloid over 55 minutes · Drug: 250 mL Colloid over 60 minutes · Drug: Intravenous Ephedrine · Drug: Intravenous Syntocinon

  • Active comparator
    Crystalloid

    250 mL crystalloid over 5 minutes followed by 500 mL crystalloid over 55 minutes then 250 mL crystalloid over 60 minutes. Cesarean delivery performed under spinal anesthesia (intrathecal bupivacaine 12.5 mg and intrathecal fentanyl 15 μg). Ultrasound assessment of the Inferior vena cava diameter. Intravenous ephedrine and intravenous syntocinon will be administered.

    Procedure: Spinal Anesthesia · Drug: Intrathecal Bupivacaine · Drug: Intrathecal Fentanyl · Procedure: Cesarean Delivery · Radiation: Ultrasound Assessment of the Inferior Vena Cava · Drug: 250 mL Crystalloid over 5 minutes · Drug: 500 mL Crystalloid over 55 minutes · Drug: 250 mL Crystalloid over 60 minutes · Drug: Intravenous Ephedrine · Drug: Intravenous Syntocinon

Interventions

  • ProcedureSpinal Anesthesia

    Performed at the L3-L4 or L4-L5 interspace using 27- or 25-gauge spinal needle

  • DrugBupivacaineStudies of BupivacaineBupivacaine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Bupivacaine 12.5 mg (2.5 mL 0.5%) will be administered in the subarachnoid space

  • DrugFentanylStudies of FentanylFentanyl pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Fentanyl 15 μg will be administered in the subarachnoid space

  • ProcedureCesarean Delivery

    Lower segment cesarean section using the Pfannenstiel incision

  • RadiationUltrasound Assessment of the Inferior Vena Cava

    The inferior vena cava largest and smallest diameters will be measured proximal to the opening of the hepatic veins in the longitudinal axis with the M-mode using a 8-2 MHz curved array ultrasound probe placed longitudinally in the subcostal region

  • Drug250 mL Colloid over 5 minutes

    6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride (voluven®) 250 mL will be administered over 5 minutes starting immediately after intrathecal injection

  • Drug250 mL Crystalloid over 5 minutes

    Ringer acetate 250 mL will be administered over 5 minutes starting immediately after intrathecal injection

  • Drug500 mL Crystalloid over 55 minutes

    Ringer acetate 500 mL will be administered over 55 minutes following colloid or crystalloid administration

  • Drug250 mL Colloid over 60 minutes

    After 60 minutes of intrathecal injection, 6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride (voluven®) 250 mL will be administered over 60 minutes

  • Drug250 mL Crystalloid over 60 minutes

    After 60 minutes of intrathecal injection, Ringer acetate 250 mL will be administered over 60 minutes

  • DrugEphedrineStudies of EphedrineEphedrine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Intravenous ephedrine 3, 5, and 10 mg will be administered when Systolic blood pressure decreases below 120, 110, and 90 mmHg, respectively.

  • DrugOxytocinStudies of OxytocinOxytocin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Immediately after delivery, syntocinon 10 IU will be added to the running crystalloid solution

06

What researchers measure

Primary outcomes

  1. Total urine output at 2 hours post-spinal

    Time frame: 2 hours after intrathecal injection

Secondary outcomes

  1. Urine output at 1 hour post-spinal

    Time frame: 1 hour after intrathecal injection

  2. Incidence of oliguria

    Total urine output at 2 hours post-spinal \<60 mL

    Time frame: 2 hours after intrathecal injection

  3. Total ephedrine dose

    Time frame: Intraoperative

  4. Pre-delivery ephedrine dose

    Time frame: From intrathecal injection until delivery

  5. Number of patients requiring ephedrine

    Time frame: Intraoperative

  6. Number of patients requiring ephedrine pre-delivery

    Time frame: From intrathecal injection until delivery

  7. Incidence of nausea and/or vomiting

    Time frame: Intraoperative

  8. Incidence of bradycardia

    Heart rate \<50 beats/minute

    Time frame: Intraoperative

  9. Maximum and minimum inferior vena cava diameters

    Time frame: Baseline, at 5 minutes post-spinal, immediately after delivery of the fetus, and at 1 and 2 hours post-spinal

  10. Inferior vena cava collapsibility index

    Time frame: Baseline, at 5 minutes post-spinal, immediately after delivery of the fetus, and at 1 and 2 hours post-spinal

  11. Neonatal Apgar score

    Time frame: At 1 and 5 minutes after delivery

07

Study locations

1 site
  • Department of Anesthesia, Mansoura University Hospitals
    Mansoura, Dakahlia 35511, Egypt
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2017 to primary completion in Jul 2021, 46 months.

Of 172 non-industry interventional studies with no phase under Pre-Eclampsia, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's 46 months is above that.

Counting every sponsor, half of 177 studies reached it within 24 months; a quarter within 10 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2017
First posted
Aug 17, 2017
StartActual
Aug 19, 2017
Primary completionActual
Jul 15, 2021
CompletionActual
Jul 15, 2021
Last update
Sep 5, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 5, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03252496
Responsible party
Mohamed Mohamed Tawfik (Lecturer, Department of anesthesia and surgical intensive care, Primary investigator, Mansoura University) — Principal investigator
First posted
Aug 17, 2017
Start date
Aug 19, 2017
Primary completion
Jul 15, 2021
Completion
Jul 15, 2021
Last update
Sep 5, 2021

Study contacts

Mohamed M Tawfik, MD
principal investigator · Mansoura University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion